Khasraw, M., Mukaro, V. R., West, L., Brandt, C., Woollett, A. M., Edwards, M., … Patil, S. (2015). Tailored neoadjuvant epirubicin and cyclophosphamide (EC) and nanoparticle albumin bound (nab)-paclitaxel for newly diagnosed breast cancer (BC). In JOURNAL OF CLINICAL ONCOLOGY (Vol. 33). Chicago, IL: AMER SOC CLINICAL ONCOLOGY.

Khasraw, Mustafa, Violet Rudo Mukaro, Linda West, Conrad Brandt, Anne Maree Woollett, Michelle Edwards, Robert Spokes, et al. “Tailored neoadjuvant epirubicin and cyclophosphamide (EC) and nanoparticle albumin bound (nab)-paclitaxel for newly diagnosed breast cancer (BC).” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 33. AMER SOC CLINICAL ONCOLOGY, 2015.

Khasraw M, Mukaro VR, West L, Brandt C, Woollett AM, Edwards M, et al. Tailored neoadjuvant epirubicin and cyclophosphamide (EC) and nanoparticle albumin bound (nab)-paclitaxel for newly diagnosed breast cancer (BC). In: JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY; 2015.

Khasraw, Mustafa, et al. “Tailored neoadjuvant epirubicin and cyclophosphamide (EC) and nanoparticle albumin bound (nab)-paclitaxel for newly diagnosed breast cancer (BC).” JOURNAL OF CLINICAL ONCOLOGY, vol. 33, no. 15, AMER SOC CLINICAL ONCOLOGY, 2015.

Khasraw M, Mukaro VR, West L, Brandt C, Woollett AM, Edwards M, Spokes R, Mitchell G, Prince K, Hayes TM, Collins IM, Guminski AD, Baron-Hay SE, Olesen IH, Bryan J, Bowles S, Wong SF, Ashley DM, Patil S. Tailored neoadjuvant epirubicin and cyclophosphamide (EC) and nanoparticle albumin bound (nab)-paclitaxel for newly diagnosed breast cancer (BC). JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY; 2015.